BCG in Bladder Cancer Treatment

March 3, 2021

&amp;amp;amp;lt;span style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” data-mce-type=”bookmark” class=”mce_SELRES_start”&amp;amp;amp;gt;&amp;amp;amp;lt;/span&amp;amp;amp;gt;

Read the podcast transcript here.

In the inaugural “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Ashish Kamat about the state of BCG in bladder cancer treatment. Dr. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr. Kamat also serves on BCAN’s Scientific Advisory Board.

In this episode, Rick and Dr. Kamat discuss what BCG is, how it is used, why there is a BCG shortage and what some therapeutic alternatives are.

Dr. Kamat can be found on Twitter at @UroDocAsh.

Disclaimer: The views and opinions expressed in this podcast are those of the speakers and guests and do not necessarily reflect the views or positions of the Bladder Cancer Advocacy Network.

Never miss an episode of “Bladder Cancer Matters” by subscribing on your favorite podcast platform.

What’s Up with Bladder Cancer and BCG with Dr. Ashish Kamat

Read Our Stories

Read Brian’s Story

Read Colleen’s Story: “It is important to take each day as it comes because the obstacles seem insurmountable in the beginning.”

Read Ronald’s Story: “Trust your gut.”

Read Anita’s Story: “We have to be our own advocates and live life as bravely and as fully as we can.”